María Gabriela Guerrina Valeta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María Gabriela Guerrina Valeta has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Cecilia Castillo
Prof. Agregada del Servicio de Oncología. Hospital de Clínicas “Dr. Manuel Quintela”. Facultad de Medicina. Universidad de la República. Montevideo, Uruguay
2 shared publications - Dahiana Amarillo
Asistente del Servicio de Oncología Clínica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
2 shared publications - Gabriel Krygier
Prof. Titular del Servicio de Oncología Clínica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República. Uruguay
2 shared publications - Guadalupe Herrera
Universidad de la República, Uruguay. Montevideo, Uruguay
2 shared publications - Natalia Camejo
Department of Clinical Oncology, School of Medicine, University of Uruguay, Montevideo, Uruguay
2 shared publications - Diego Santana
Medical Oncology Department, Hospital de Clínicas ‘Dr. Manuel Quintela’, Facultad de Medicina, Universidad de la República, Montevideo11600, Uruguay
1 shared publication
Latest Publications
- 5 May 2025
- Published by Medwave Estudios Limitada in Medwave
- Vol. 25 (04) , e3045
Influence of different treatment modalities on the sexual function of breast cancer survivors: An observational ambispective study
Introduction Advances in treatment have improved the survival rates of patients diagnosed with breast cancer. However, the number of women experiencing long-term consequences has also increased, affecting their quality of life, including sexual function. Objectives To evaluate the prevalence of sexual dysfunction as measured by the Female Sexual Function Index, its association with treatment modalities in Uruguayan breast cancer survivors, and to compare the questionnaire scores by age group (50 years or older versus under 50 years). Methods This ambispective observational study included patients diagnosed with early-stage breast cancer (I to III) who had completed surgery, chemotherapy, and radiotherapy treatments at least 12 months before inclusion. Patients completed the Female Sexual Function Index questionnaire, and the data were analyzed using simple and multiple binary logistic models to assess the relationship between treatment modalities and sexual dysfunction. Additionally, differences in Female Sexual Function Index scores between age groups were analyzed. Results A total of 149 patients were included; 67.1% underwent breast-conserving surgery, 68.5% received chemotherapy, 92.6% radiotherapy, and 95.3% hormone therapy. Sexual dysfunction, defined as a score ≤ 26.55 on the questionnaire, was present in 58.3% of patients. Multivariate analysis indicated a higher risk of sexual dysfunction in patients who underwent total mastectomy, were treated with chemotherapy, or used gonadotropin-releasing hormone agonists. Conclusions Although this study highlights the impact of certain treatment modalities on sexual function, the results should be interpreted considering the characteristics of the population and potential biases. These findings can guide clinicians in planning treatments to improve the quality of life of sexually active breast cancer patients.
- 5 May 2025
- Published by Medwave Estudios Limitada in Medwave
- Vol. 25 (04) , e3045
Influence of different treatment modalities on the sexual function of breast cancer survivors: An observational ambispective study
Introduction Advances in treatment have improved the survival rates of patients diagnosed with breast cancer. However, the number of women experiencing long-term consequences has also increased, affecting their quality of life, including sexual function. Objectives To evaluate the prevalence of sexual dysfunction as measured by the Female Sexual Function Index, its association with treatment modalities in Uruguayan breast cancer survivors, and to compare the questionnaire scores by age group (50 years or older versus under 50 years). Methods This ambispective observational study included patients diagnosed with early-stage breast cancer (I to III) who had completed surgery, chemotherapy, and radiotherapy treatments at least 12 months before inclusion. Patients completed the Female Sexual Function Index questionnaire, and the data were analyzed using simple and multiple binary logistic models to assess the relationship between treatment modalities and sexual dysfunction. Additionally, differences in Female Sexual Function Index scores between age groups were analyzed. Results A total of 149 patients were included; 67.1% underwent breast-conserving surgery, 68.5% received chemotherapy, 92.6% radiotherapy, and 95.3% hormone therapy. Sexual dysfunction, defined as a score ≤ 26.55 on the questionnaire, was present in 58.3% of patients. Multivariate analysis indicated a higher risk of sexual dysfunction in patients who underwent total mastectomy, were treated with chemotherapy, or used gonadotropin-releasing hormone agonists. Conclusions Although this study highlights the impact of certain treatment modalities on sexual function, the results should be interpreted considering the characteristics of the population and potential biases. These findings can guide clinicians in planning treatments to improve the quality of life of sexually active breast cancer patients.
- Open Access
- 1 January 2024
- Published by Knowledge Enterprise Journals in Medical Research Archives
- Vol. 12 (6)
Hormone therapy adherence in breast cancer: Predictive factors in Uruguay
Background/Aim: Adjuvant hormone therapy (HT) significantly improves survival in patients with hormone receptor-positive breast cancer, yet adherence to this therapy is critical and tends to decrease over time. This study aims to identify risk factors for suboptimal adherence to adjuvant HT among patients treated at the Hospital de Clínicas and the Hospital Departamental de Soriano, Uruguay, to inform future strategies to improve adherence. Materials and Methods: A retrospective, cross-sectional study was conducted, including 96 breast cancer patients in stages I-III treated with HT for at least three years. Adherence was assessed using the Morisky-Green questionnaire. Statistical analysis was employed to estimate the odds ratios (OR) for non-adherence, with a significance threshold of α=0.05. Results: Out of the 96 patients included, 22.9% demonstrated suboptimal adherence to hormone therapy. Analysis revealed that the use of tamoxifen (adjusted OR of 4.86, p<0.05) and living with others were significant predictors of non-adherence. The aggressiveness of the treatment did not show a statistically significant correlation with adherence. Additionally, the analysis highlighted that sociodemographic characteristics, such as marital status and employment situation, did not directly influence adherence, underscoring the complexity of factors contributing to treatment adherence. Intriguingly, the analysis showed a trend towards greater adherence among postmenopausal patients and those with a history of combined treatment of tamoxifen and aromatase inhibitors, though these results warrant further exploration. Conclusion: Suboptimal adherence to adjuvant HT in breast cancer patients is significantly influenced by the type of hormone therapy prescribed and the patient's social environment. It is necessary to develop personalized interventions that address these factors to improve adherence.
- 1 January 2024
- Published by Knowledge Enterprise Journals in Medical Research Archives
- Vol. 12 (6)
Open AccessHormone therapy adherence in breast cancer: Predictive factors in Uruguay
Background/Aim: Adjuvant hormone therapy (HT) significantly improves survival in patients with hormone receptor-positive breast cancer, yet adherence to this therapy is critical and tends to decrease over time. This study aims to identify risk factors for suboptimal adherence to adjuvant HT among patients treated at the Hospital de Clínicas and the Hospital Departamental de Soriano, Uruguay, to inform future strategies to improve adherence. Materials and Methods: A retrospective, cross-sectional study was conducted, including 96 breast cancer patients in stages I-III treated with HT for at least three years. Adherence was assessed using the Morisky-Green questionnaire. Statistical analysis was employed to estimate the odds ratios (OR) for non-adherence, with a significance threshold of α=0.05. Results: Out of the 96 patients included, 22.9% demonstrated suboptimal adherence to hormone therapy. Analysis revealed that the use of tamoxifen (adjusted OR of 4.86, p<0.05) and living with others were significant predictors of non-adherence. The aggressiveness of the treatment did not show a statistically significant correlation with adherence. Additionally, the analysis highlighted that sociodemographic characteristics, such as marital status and employment situation, did not directly influence adherence, underscoring the complexity of factors contributing to treatment adherence. Intriguingly, the analysis showed a trend towards greater adherence among postmenopausal patients and those with a history of combined treatment of tamoxifen and aromatase inhibitors, though these results warrant further exploration. Conclusion: Suboptimal adherence to adjuvant HT in breast cancer patients is significantly influenced by the type of hormone therapy prescribed and the patient's social environment. It is necessary to develop personalized interventions that address these factors to improve adherence.